Skip to content

Initial outcomes of Rayner Galaxy IOL

Initial outcomes of a new generation, AI designed spiral optic, non-diffractive multifocal IOL - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096348
Enrollment
100
Registered
2025-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H259- Unspecified age-related cataract

Interventions

Intervention1: To assess visual outcomes and induced aberrations after implantation of Rayner Galaxy Lens: postoperative visits at day 1, 2 weeks, 3 months and 12 months Control Intervention1: Assessm

Sponsors

nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: bilateral implantation of the same IOL cataractous eyes with no other ocular comorbidity, regular corneal topography and corneal astigmatism preoperative angle kappa less than 5 degrees and alpha less than 6 degrees patient desiring spectacle independence and having realistic expectation availability, willingness and sufficient cognitive awareness to comply with examination procedures,

Exclusion criteria

Exclusion criteria: presence of active ocular disease in the operative eye such as chronic uveitis, proliferative diabetic retinopathy, chronic glaucoma unresponsive to medication, corneal decompensation and corneal endothelial cell insufficiency, subjects with any systemic disease that could increase operative risk or confound the outcome, any patient who is taking part in another study involving ocular surgery,s ignificant irregular corneal astigmatism, pupil abnormalities – non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic or scotopic conditions..

Design outcomes

Primary

MeasureTime frame
To assess visual outcomes and induced aberrations after implantation of Rayner Galaxy LensTimepoint: postoperative visits at day 1, 2 weeks, 3 months and 12 months

Secondary

MeasureTime frame
Assessment of contrast sensitivity and defocus curve.Timepoint: postoperative visits at day 1, 2 weeks, 3 months and 12 months

Countries

India

Contacts

Public ContactDr Sneha G V

Nethradhama Super Speciality Eye Hospital

sush.samak@gmail.com9448071800

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026